Lantern Pharma(LTRN.US)

Last Updated 19:00:00 ET
longbridge loading

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

PUBT·
US
LTRN
+1.17%
US
XLV
+0.84%
US
IHE
+0.47%
PUBT·
US
LTRN
+1.17%
US
XLV
+0.84%
US
IHE
+0.47%

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC | LTRN Stock News

StockTitan·
US
LTRN
+1.17%
US
ARKG
-1.49%
US
VHT
+0.63%
StockTitan·
US
LTRN
+1.17%
US
ARKG
-1.49%
US
VHT
+0.63%

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga_article·
US
GOSS
+5.55%
US
LTRN
+1.17%
US
AIM
-15.37%
benzinga_article·
US
GOSS
+5.55%
US
LTRN
+1.17%
US
AIM
-15.37%

Lantern Pharma | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.3

Earnings Watch·
US
LTRN
+1.17%
Earnings Watch·
US
LTRN
+1.17%

Lantern Pharma raises capital, plans AI platform spinoff

Tip Ranks·
US
LTRN
+1.17%
US
IBB
-0.71%
US
FBT
-0.28%
Tip Ranks·
US
LTRN
+1.17%
US
IBB
-0.71%
US
FBT
-0.28%

Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw

TradingView·
US
LTRN
+1.17%
TradingView·
US
LTRN
+1.17%

Pre-market hot trades in US stocks: Lantern Pharma up 7.17% in pre-market; AST SpaceMobile up 3.30% in pre-market

Price Alert·
US
LTRN
+1.17%
US
ASTS
-6.99%
Price Alert·
US
LTRN
+1.17%
US
ASTS
-6.99%

Lantern Pharma shares are trading higher after Lantern Pharma announced up to a $9.25 million direct offering with existing shareholders.

benzinga_article·
US
LTRN
+1.17%
US
XBI
-1.75%
US
BBH
-0.36%
benzinga_article·
US
LTRN
+1.17%
US
XBI
-1.75%
US
BBH
-0.36%
© 2026 Longbridge｜Disclaimer